Gile JJ, Mondello P, Wang Z, Li Y, Bansal R, Gandhi S, Zhang H, Babadi E, Martinez K, McCoy G, Shao Z, Regan K, Hathcock MA, Wang P, Wang J, Al Saleh AS, Ruan G, Ansell SM, Villasboas-Bisneto JC, Khurana A, Durani U, Wang Y, Hampel PJ, Rosenthal A, Munoz J, Merono E, Castro Januario E, Murthy HS, Kharfan-Dabaja M, Kenderian SS, Kim JJ, Shen R, Mattie M, Lin Y, Witzig TE. Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival. Experimental Hematology and Oncology. Under review.
Gile JJ, Maurer M, Ruan GJ, Abeykoon JP, Heimgartner JR, Baumann NA, McMahon MM, Lin Y, Witzig TE. Low magnesium levels and prognosis in newly diagnosed Diffuse Large B Cell Lymphoma. The Oncologist, Volume 29, Issue 12, December 2024, Pages e1779–e1782, https://doi.org/10.1093/oncolo/oyae255.
Gow-Lee V, Abu Saleh OM, Harris CE, Gile JJ, Akhiyat N, Chesdachai S. Outcomes of Invasive Fungal Infections Treated with Isavuconazole: A Retrospective Review. Pathogens. 2024 Oct 11;13(10):886. doi: 10.3390/pathogens13100886. PMID: 39452757; PMCID: PMC11510498.
Gairing SJ, Mildenberg P, Gile JJ, et al. - Evaluation of prognostic scores in HCC patients undergoing 1L immunotherapy with atezolizumab and bevacizumab – development and validation of the CABLE score. Journal of Hepatology. Submitted.
Marell P, Kournoutas I, Gile JJ, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14:oyae342. doi: 10.1093/oncolo/oyae342. Epub ahead of print. PMID: 39674576.
Storandt MH, Zemla TJ, Patell K, Naleid N, Gile JJ, Tran NH, Chakrabarti S, Jin Z, Borad M, Mahipal A. Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study, The Oncologist, 2024; https://doi.org/10.1093/oncolo/oyae142.
Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J. 2023 Nov 13;13(1):169. doi: 10.1038/s41408-023-00942-3. PMID: 37957158; PMCID: PMC10643454.
Palmer ME, Gile JJ, Storandt MH, Jin Z, Zemla TJ, Tran NH, Mahipal A. Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study. Cancers (Basel). 2023 Oct 6;15(19):4867. doi: 10.3390/cancers15194867. PMID: 37835561; PMCID: PMC10571707.
Marell PS, Diehn FE, Gile JJ. Acute Pontine Osmotic Demyelination Syndrome at Presentation of Lymphoma in Association With Hypoalbuminemia. Mayo Clin Proc. 2023 Apr;98(4):507-508. doi: 10.1016/j.mayocp.2022.11.016. PMID: 37019512.
Ng CT, Gonzalez Bonilla HM, Chang I, Aung MT, Gile JJ, Pereira NL, Villasboas Bisneto JC, Johnston PB, Villarraga HR, Rodriguez-Porcel MG, Lin G, Lin Y, Herrmann J. CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement. JACC Case Rep. 2023 Apr 21;15:101840. doi: 10.1016/j.jaccas.2023.101840. PMID: 37283829; PMCID: PMC10240233.
Mahipal A, Palmer M, Gile JJ, Kim R. Durvalumab: A PD-L1 blocking antibody for the treatment of adult patients with locally advanced or metastatic biliary tract cancer. TouchREVIEWS in Oncology & Hematology. 2023;19(1):22-26. DOI: https://doi.org/10.17925/OHR.2023.19.1.22.
Gile JJ, McGarrah PW, Leventakos K, Sonbol MB, Starr JS, Eiring RA, Hobday TJ, Halfdanarson TR. Efficacy of checkpoint inhibitors in combination with chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinoma. J Neuroendocrinol. 2023 May;35(5):e13283. doi: 10.1111/jne.13283. Epub 2023 May 25. PMID: 37229903
Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma. Cancers. 2022 Oct 22;14(21):5173. doi: 10.3390/cancers14215173. PMID: 36358592; PMCID: PMC9657200.
Gile, JJ, Wookey, V., Zemla, T.J. et al. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Targ Oncol (2022). https://doi.org/10.1007/s11523-022-00914-w
Al-Toubah T, Halfdanarson TH, Gile JJ, Sommerer K, Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open. 2022 Feb;7(1):100364. doi: 10.1016/j.esmoop.2021.100364. Epub 2021 Dec 29. PMID: 34973511; PMCID: PMC8728436.
Gile JJ, Lopez CL, Ruan GJ, Hathcock MA, Abeykoon JP, Heimgartner JR, Baumann NA, McMahon MM, Micallef IN, Johnston PB, Villasboas Bisneto JC, Porrata LF, Paludo J, Ansell SM, Hogan WJ, Witzig TE. Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood Cancer J. 11, 65 (2021). https://doi.org/10.1038/s41408-021-00452-0.
Gile JJ, Liu A, McGarrah P, Eiring R, Hobday T, Starr J, Sonbol M, Halfdanarson TR. Efficacy of checkpoint inhibitors in neuroendocrine neoplasms: Mayo Clinic experience. Pancreas. 2021;50(4):500-505. doi: 10.1097/MPA.0000000000001794.
Gile JJ, Fang-Shu O, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma W, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Instituion Cohort Experience. JCO Precis Oncol. 2021 Jul 28;5:PO.21.00064. doi: 10.1200/PO.21.00064. PMID: 34778691; PMCID: PMC8575436.
Gile JJ, Heimgartner J, Ruan G, McMahon MM, Witzig T. Hypomagnesemia and Outcomes in Hematologic Malignancies. J Cell Immunol. 2020; 2(5): 245-249.
Gile JJ, Sara JDS, Mueller MR. Systemic lupus erythematosus multiorgan flare with quiescent serologic markers. BMJ Case Reports CP 2021;14:e239048.
Gile JJ, Oyama Y, Shuff S and Eckle T., “A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction”, Current Pharmaceutical Design (2020) 26: 4330. https://doi.org/10.2174/1381612826666200415171622
Gile JJ, Ruan G, Abeykoon J, Macon W, McMahon MM, Witzig T. Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt Lymphoma. Leukemia & Lymphoma. 2020;1-3. doi:10.1080/10428194.2020.1759056
Gile JJ, Ruan G, Abeykoon J, McMahon MM, Witzig T. Magnesium: The Overlooked Electrolyte in Blood Cancers? Blood Reviews. 2020;100676. Doi:10.1016/j.blre.2020.100676
Gile JJ, Satterfield B, Leasure E. 37-Year Old Woman with Bilateral Lower Extremity Edema, Proteinuria, and Microscopic Hematuria. Mayo Clinic Proceedings. 2020;95(8):e81-e86. Doi:10.1016/j.mayocp.2019.12.035
Oyama Y, Bartman CM, Gile JJ, Sehrt D, Eckle T. The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury. Curr Pharm Des. 2018;24(28):3376–3383. doi:10.2174/1381612824666180924102530
Gile JJ, Scott B, Eckle T. The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium. Crit Care Med. 2018;46(6):e600–e608. doi:10.1097/CCM.0000000000003077
Hsu YA, Gile JJ, Perez JG, et al. The Dorsal Medial Habenula Minimally Impacts Circadian Regulation of Locomotor Activity and Sleep. J Biol Rhythms. 2017;32(5):444–455. doi:10.1177/0748730417730169
Oyama Y, Bartman CM, Gile JJ, Eckle T. Circadian MicroRNAs in Cardioprotection. Curr Pharm Des. 2017;23(25):3723–3730. doi:10.2174/1381612823666170707165319
Gile JJ, Eckle T. ADORA2b Signaling in Cardioprotection. J Nat Sci. 2016;2(10):e222.
Kalume F, Oakley JC, Westenbroek RE, Gile JJ, de la Iglesia HO, Scheuer T, Catterall WA. Sleep impairment and reduced interneuron excitability in a mouse model of Dravet Syndrome. Neurobiol Dis. 2015;77:141–154. doi:10.1016/j.nbd.2015.02.016
Smarr BL, Gile JJ, de la Iglesia HO. Oestrogen-independent circadian clock gene expression in the anteroventral periventricular nucleus in female rats: possible role as an integrator for circadian and ovarian signals timing the luteinising hormone surge. J Neuroendocrinol. 2013;25(12):1273–1279. doi:10.1111/jne.12104
